Finch Therapeutics Group, Inc. Common Stock
FNCH
FNCH was delisted on the 24th of May, 2024.
17 hedge funds and large institutions have $2.16M invested in Finch Therapeutics Group, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 17 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
42% less capital invested
Capital invested by funds: $3.75M → $2.16M (-$1.6M)
48% less funds holding
Funds holding: 33 → 17 (-16)
94% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$5.55K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.69K |
| 3 |
Morgan Stanley
New York
|
+$1.02K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$277 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$51 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
Bleichroeder LP
New York
|
-$267K |
| 2 |
SW
SVB Wealth
Boston,
Massachusetts
|
-$99.5K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$81.9K |
| 4 |
MP
MSD Partners
New York
|
-$60.3K |
| 5 |
BP
Ballentine Partners
Waltham,
Massachusetts
|
-$56.4K |
FNCH Hedge Fund Activity: Q2 2023 in Review
17 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q2 2023, worth a combined $2.16M — down 42% from $3.75M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of FNCH and 1 opened new positions — a net loss of 16 holders — while 8 trimmed existing stakes and 5 added.
The largest buyer was UBS Group, adding an estimated $5.55K. The largest seller was Bleichroeder LP, cutting an estimated $267K.
- 17 institutional investors held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q2 2023, down from 33 in Q1 2023.
- Funds reported $2.16M of Finch Therapeutics Group, Inc. Common Stock stock for Q2 2023, down 42% quarter-over-quarter.
- 1 fund opened new Finch Therapeutics Group, Inc. Common Stock positions in Q2 2023 and 17 closed out, a net change of -16 holders.
- The largest Finch Therapeutics Group, Inc. Common Stock buyer in Q2 2023 was UBS Group, an estimated $5.55K added.
- The largest Finch Therapeutics Group, Inc. Common Stock seller in Q2 2023 was Bleichroeder LP, an estimated $267K sold.
Based on aggregated 13F filings for Q2 2023.